Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

0.5740
-0.0348-5.72%
Volume:303.14K
Turnover:176.40K
Market Cap:12.25M
PE:-0.28
High:0.6100
Open:0.6016
Low:0.5709
Close:0.6088
52wk High:2.24
52wk Low:0.5709
Shares:21.33M
Float Shares:16.75M
Volume Ratio:1.60
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0427
EPS(LYR):-2.6164
ROE:-119.92%
ROA:-60.95%
PB:1.23
PE(LYR):-0.22

Loading ...

Longeveron Q2 EPS $(0.33) Beats $(0.35) Estimate, Sales $316.000K Miss $414.650K Estimate

Benzinga
·
Aug 14

Longeveron Inc - Elpis Ii Trial Results Expected in Q3 2026

THOMSON REUTERS
·
Aug 14

Longeveron: Sees Existing Cash to Fund Operating Expenses and Capital Expenditure Need Into Q1 2026

THOMSON REUTERS
·
Aug 14

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 14

Longeveron Announces Closing of up to $17.5 Million Public Offering

THOMSON REUTERS
·
Aug 12

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

GlobeNewswire
·
Aug 12

Longeveron Shares Fall After Company Prices Public Offering

MT Newswires Live
·
Aug 09

Longeveron Inc - Short-Term Warrants Exercisable at $0.85 per Share

THOMSON REUTERS
·
Aug 09

Longeveron Inc - Gross Proceeds From Offering Expected to Be $5 Mln

THOMSON REUTERS
·
Aug 09

Longeveron Announces up to $17.5 Million Public Offering

THOMSON REUTERS
·
Aug 09

Longeveron Announces Up To $17.5 Million Public Offering

GlobeNewswire
·
Aug 09

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

GlobeNewswire
·
Aug 05

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

GlobeNewswire
·
Jul 21

Longeveron Gets US FDA Approval for Phase 2 Trial of Laromestrocel

MT Newswires Live
·
Jul 08

BRIEF-Longeveron® Announces U.S. FDA Approval Of Ind Application

Reuters
·
Jul 08

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

GlobeNewswire
·
Jul 08

Press Release: Longeveron(R) Appoints Than Powell as Chief Business Officer

Dow Jones
·
Jun 26

BRIEF-Longeveron® Announces Completion Of Enrollment Of Pivotal Phase 2B Clinical Trial

Reuters
·
Jun 24

Longeveron Inc. Concluded Annual Stockholders Meeting

Reuters
·
Jun 17